Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

Table 1 Relationship of Antibiotic susceptibility with Erava MIC value levels in MRSA isolates

Antibiotic	N	Resistance rate^a (%)	MIC breakpoints (mg/L)	No. isolates each level	Erava MIC (mg/L) data
					No. isolates with each MIC				MIC₅₀/MIC₉₀
					≤0.125	0.25	0.5	1.0	MIC₅₀/MIC₉₀
Total	138				54	78	6	0	0.25/0.25
Amikacin	134	47.76	≤16	70	33	33	4	0	0.25/0.25
			32	3	0	3	0	0	0.25/0.25
			≥64	61	19	41	1	0	0.25/0.5
Erythromycin	137	95.62	≤0.5	6	4	2	0	0	0.25/0.25
			1–4	1	0	1	0	0	0.25/0.25
			≥8	130	50	75	5	0	0.25/0.25
Ciprofloxacin	133	50.38	≤1	66	32	31	3	0	0.25/0.25
			2	1	0	1	0	0	0.25/0.25
			≥4	66	19	45	2	0	0.25/0.25
Rifampicin	135	16.30	≤1	113	45	64	4	0	0.25/0.25
			≥4	22	8	14	0	0	0.25/0.25
Tetracycline	138	65.94	≤4	47	31	12	4	0	0.125/0.25
			8	17	3	14	0	0	0.25/0.25
			≥16	74	20	52	2	0	0.25/0.25
Tobramycin	133	50.38	≤4	66	32	31	3	0	0.25/0.25
			≥16	67	19	46	2	0	0.25/0.25
Nitrofurantoin	136	2.94	≤32	132	51	76	5	0	0.25/0.25
			64	2	2	0	0	0	0.125/0.25
			≥128	2	0	2	0	0	0.25/0.25
Quinupristin	124	2.42	≤1	121	47	71	3	0	0.25/0.25
			2	1	1	0	0	0	0.125
			≥4	2	1	1	0	0	0.0625/0.125

ISSN: 1471-2180